CRISPR Therapeutics AG

The US Food and Drug Administration has successfully helped pull stalled cell and gene therapy programs off the cutting room floor in recent years and wants sponsors who might benefit from the agency’

SV Health Investors announced the final closing for its second Dementia Discovery Fund, DDF-2, with $269m in commitments from investors and non-profit organizations willing to put their money behind s

CRISPR Therapeutics is stepping outside its comfort zone by partnering up with Sirius Therapeutics to develop small interfering RNA (siRNA) therapies, particularly Sirius’s SRSD107 for thromboembolic

The first clinical data from CRISPR Therapeutics’ in vivo gene-editing candidate, CTX310, look promising, with steep drops in low-density lipoprotein (LDL)-cholesterol and triglyceride levels. The r